SIGLEC9 and esophageal squamous cell carcinoma: SIGLEC9 interacts with MUC1, which therefore induces M2 polarization of TAMs, formation of the immunosuppressive TME, nuclear translocation of β-catenin, and ferroptosis resistance of ESCC cells (Fig S3).